A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K39/00—Medicinal preparations containing antigens or antibodies
A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K39/00—Medicinal preparations containing antigens or antibodies
A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
A61K2039/507—Comprising a combination of two or more separate antibodies
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K39/00—Medicinal preparations containing antigens or antibodies
A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K39/00—Medicinal preparations containing antigens or antibodies
A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K39/00—Medicinal preparations containing antigens or antibodies
A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P35/00—Antineoplastic agents
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K16/3023—Lung
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K16/303—Liver or Pancreas
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K16/3038—Kidney, bladder
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K16/3046—Stomach, Intestines
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K16/3061—Blood cells
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K16/46—Hybrid immunoglobulins
C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K2317/00—Immunoglobulins specific features
C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K2317/00—Immunoglobulins specific features
C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K2317/00—Immunoglobulins specific features
C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K2317/00—Immunoglobulins specific features
C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K2317/00—Immunoglobulins specific features
C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
C07K2317/52—Constant or Fc region; Isotype
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K2317/00—Immunoglobulins specific features
C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
C07K2317/71—Decreased effector function due to an Fc-modification
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K2317/00—Immunoglobulins specific features
C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K2317/00—Immunoglobulins specific features
C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
C07K2317/75—Agonist effect on antigen
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K2317/00—Immunoglobulins specific features
C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
1. A multispecific antibody, comprising: (1) a single cancer-specific antigen-binding Fab domain; (2) a single CD137 or CD40-binding domain; and 5 (3) an FcRn-binding domain; wherein the FcRn-binding domain is a mutant antibody Fc region having decreased Fc? receptor-binding activity.
2. A pharmaceutical composition comprising as an active ingredient the antigen-binding molecule of claim 1. 10
3. The pharmaceutical composition of claim 2 wherein the pharmaceutical composition is a cytotoxicity-inducing pharmaceutical composition.
4. The pharmaceutical composition of claim 2 or 3, for use in a method for the treatment of cancer.
5. A pharmaceutical composition comprising a combination of a first antigen-binding molecule 15 of claim 1, and a second antigen-binding molecule that comprises: (1) a cancer-specific antigen-binding domain; and (2) a CD3-binding domain.
6. The pharmaceutical composition of claim 5 wherein the pharmaceutical composition is a cytotoxicity-inducing pharmaceutical composition. 20
7. The pharmaceutical composition of claim 5 or 6 wherein the second antigen-binding molecule is a multispecific antibody.
8. The pharmaceutical composition of any one of claim 5 to 7, wherein the second antigen-binding molecule is an antigen-binding molecule that further comprises an FcRn-binding domain, wherein the FcRn-binding domain is a mutant antibody Fc region 25 having decreased Fc? receptor-binding activity.
9. Use of a multispecific antibody, comprising: (1) a single cancer-specific antigen-binding Fab domain; and (2) a single CD137 or CD40-binding domain; and (3) an FcRn-binding domain, wherein the FcRn-binding domain is a mutant antibody Fc region having decreased Fc? receptor-binding activity, in the manufacture of a medicament for use in the treatment of cancer. 5
10. Use of claim 9, wherein the medicament is a cytotoxicity-inducing medicament.
11. Use of claim 9 or 10, wherein the medicament further comprises a second antigen-binding molecule, that comprises: (1) a cancer-specific antigen-binding domain; and (2) a CD3-binding domain. 10
12. Use of claim 9 or 10, wherein the medicament is to be administered, or is in a form for administration concomitantly, simultaneously or separately with a second antigen-binding molecule that comprises: (1) a cancer-specific antigen-binding domain; and (2) a CD3-binding domain. 15
13. Use of claim 11 or 12 wherein the second antigen-binding molecule is a multispecific antibody.
14. Use of claim 11 or 12, wherein the second antigen-binding molecule is an antigen-binding molecule that further comprises an FcRn-binding domain, wherein the FcRn-binding domain is a mutant antibody Fc region having decreased Fc? receptor-binding activity. 20
15. The multispecific antibody of claim 1, substantially as herein described with reference to any example thereof, with or without reference to the figures.
16. The pharmaceutical composition of any one of claims 2 to 8, substantially as herein described with reference to any example thereof, with or without reference to the figures.
17. Use according to any one of claims 9 to 14, substantially as herein described with reference 25 to any example thereof, with or without reference to the figures.